Author Topic: COVID-19 in patients w/MS undergoing disease-modifying treatments  (Read 57 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis Journal (December 2021)--"COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments":


https://journals.sagepub.com/doi/full/10.1177/1352458520971817
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
In the New England Journal of Medicine Journal Watch (April 15, 2022) there is a "Report from the 2022 American Academy of Neurology Annual Meeting" that includes this as one of several highlighted presentations:


Quote
COVID-19 RATES HIGH AMONG VACCINATED MS PATIENTS ON CERTAIN DISEASE-MODIFYING THERAPIES

Patients with multiple sclerosis (MS) who are fully vaccinated against COVID-19 and taking the disease-modifying drug ocrelizumab have higher rates of SARS-CoV-2 infection and hospitalization than those receiving other disease-modifying therapies, according to a new study. Patients taking fingolimod also had a higher rate of infection.

Using U.K. health databases, researchers assessed the incidence of SARS-CoV-2 infection and COVID-19-related hospitalization among roughly 38,000 patients with multiple sclerosis who were receiving disease-modifying therapies and had received two doses of COVID-19 vaccine.

From December 2020 to January 2022, the incidence of SARS-CoV-2 infection was 24% for patients who were taking ocrelizumab, 22% for fingolimod, and 11% to 16% for other disease-modifying therapies. Among those infected, the hospitalization rate was highest for ocrelizumab, at 7%, followed by 4% for fingolimod and 1% to 4% for other disease-modifying therapies.

Our clinician-guide, Dr. Seemant Chaturvedi, said: "This study provides thought-provoking data on the potential efficacy of COVID-19 vaccinations for certain MS patients on disease-modifying therapies."
« Last Edit: April 19, 2022, 09:42:51 pm by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed (August 4, 2022)--"Severity of COVID-19 infection among patients with multiple sclerosis treated with interferon-β":


https://pubmed.ncbi.nlm.nih.gov/35917745/
« Last Edit: August 04, 2022, 11:27:54 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
112 Views
Last post June 01, 2017, 02:12:21 pm
by agate
0 Replies
112 Views
Last post September 26, 2017, 03:41:45 pm
by agate
0 Replies
37 Views
Last post April 07, 2020, 12:07:42 pm
by agate
2 Replies
79 Views
Last post May 19, 2020, 08:56:17 pm
by agate
6 Replies
141 Views
Last post March 01, 2021, 09:16:53 pm
by agate